|
Thrombosis
|
0.200 |
Biomarker
|
phenotype |
RGD |
PI 3-kinase p110beta: a new target for antithrombotic therapy.
|
15834429 |
2005 |
|
Prostatic Neoplasms
|
0.370 |
AlteredExpression
|
group |
LHGDN |
Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
|
18372911 |
2008 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells.
|
17676480 |
2007 |
|
Smoking
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer.
|
26053186 |
2015 |
|
Smoking Behaviors
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer.
|
26053186 |
2015 |
|
Malignant neoplasm of breast
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant Head and Neck Neoplasm
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Breast Carcinoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Head and Neck Carcinoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Head and Neck Neoplasms
|
0.300 |
CausalMutation
|
group |
CGI |
|
|
|
|
Neoplasm of uncertain or unknown behavior of breast
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Breast adenocarcinoma
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
These results demonstrate a critical function of PI3K-PDK1 signaling upstream of MALT1 protease and NF-κB in distinct ABC DLBCL cells and provide a rationale for the pharmacologic use of PI3K inhibitors in DLBCL therapy.
|
21173233 |
2011 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Prostatic Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Schizophrenia
|
0.370 |
Biomarker
|
disease |
CTD_human |
Increased exonic de novo mutation rate in individuals with schizophrenia.
|
21743468 |
2011 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, through this review, one could easily scan first and second generation inhibitors for PI3K/Akt/mTOR pathway besides targeted therapies for breast cancer and the precise role of mTOR.
|
27848885 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
We analyzed cancer-specific biclusters and found that the PI3K/Akt signaling pathway is strongly enriched with targets of a few miRNAs in breast cancer and diffuse large B-cell lymphoma.
|
30820547 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cell-based assays centered on these differences and using uncorrelated drug effects reveals novel synergistic combinations for the treatment of breast cancer dependent on PI3K-mTOR signaling.
|
27553366 |
2016 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The data presented here identify an alternative survival signal that is dependent on PLD and mTOR and is active in a breast cancer cell line where the PI3K survival pathway is not active.
|
15580312 |
2005 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT pathway and phosphatase and tensin homolog (PTEN) aberrations are common in breast cancer.
|
26758558 |
2016 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
TGF-β, FGF, NFκB, WNT, PI3K, and JAK-STAT signaling pathways, as the key pathways involved in breast cancer development and metastasis, are evidently regulated by several genes in all three signatures.
|
24493024 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Her2-induced signaling pathways include MAPK and PI3K/Akt, of which the latter has been shown to be critical for Her2(+) breast cancer cell growth and survival.
|
19946332 |
2010 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
PI3K pathway activation is associated with resistance to lapatinib and trastuzumab in breast cancers, without chemotherapy.
|
29110152 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer.
|
30454896 |
2018 |